Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALLO NASDAQ:MNOV NASDAQ:PBYI NYSE:VOR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLOAllogene Therapeutics$1.11-2.6%$1.19$0.86▼$3.78$252.94M0.363.72 million shs1.74 million shsMNOVMediciNova$1.27-0.8%$1.30$1.13▼$2.55N/A0.4366,713 shs11,292 shsPBYIPuma Biotechnology$4.54-3.6%$4.15$2.32▼$6.07$237.25M1.38735,792 shs369,368 shsVORVor Biopharma$1.80-10.4%$2.12$0.13▼$3.29$228.03M2.057.65 million shs6.04 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLOAllogene Therapeutics0.00%+1.79%+9.62%-21.38%-54.03%MNOVMediciNova+1.59%-2.29%-5.19%-5.88%-32.98%PBYIPuma Biotechnology+3.29%-7.83%+27.64%+33.05%+103.02%VORVor Biopharma+1.52%-1.47%-2.90%+813.64%+84.40%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLOAllogene Therapeutics$1.11-2.6%$1.19$0.86▼$3.78$252.94M0.363.72 million shs1.74 million shsMNOVMediciNova$1.27-0.8%$1.30$1.13▼$2.55N/A0.4366,713 shs11,292 shsPBYIPuma Biotechnology$4.54-3.6%$4.15$2.32▼$6.07$237.25M1.38735,792 shs369,368 shsVORVor Biopharma$1.80-10.4%$2.12$0.13▼$3.29$228.03M2.057.65 million shs6.04 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLOAllogene Therapeutics0.00%+1.79%+9.62%-21.38%-54.03%MNOVMediciNova+1.59%-2.29%-5.19%-5.88%-32.98%PBYIPuma Biotechnology+3.29%-7.83%+27.64%+33.05%+103.02%VORVor Biopharma+1.52%-1.47%-2.90%+813.64%+84.40%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALLOAllogene Therapeutics 2.75Moderate Buy$8.44660.76% UpsideMNOVMediciNova 3.50Strong Buy$7.00451.18% UpsidePBYIPuma Biotechnology 3.00Buy$7.0054.19% UpsideVORVor Biopharma 2.56Moderate Buy$6.07237.04% UpsideCurrent Analyst Ratings BreakdownLatest MNOV, PBYI, ALLO, and VOR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/27/2025MNOVMediciNovaD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.008/14/2025VORVor BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$3.008/4/2025ALLOAllogene TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Perform8/4/2025ALLOAllogene TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral7/24/2025MNOVMediciNovaD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.006/30/2025VORVor BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$3.006/26/2025VORVor BiopharmaWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral ➝ Outperform6/16/2025MNOVMediciNovaB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy ➝ Strong-Buy$6.00 ➝ $5.00(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLOAllogene Therapeutics$20K12,314.34N/AN/A$2.01 per share0.55MNOVMediciNova$1MN/AN/AN/A$1.07 per shareN/APBYIPuma Biotechnology$230.50M0.99$0.82 per share5.53$1.88 per share2.41VORVor BiopharmaN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLOAllogene Therapeutics-$257.59M-$1.11N/AN/AN/AN/A-55.99%-42.75%11/6/2025 (Estimated)MNOVMediciNova-$11.04M-$0.25N/AN/AN/AN/A-23.12%-21.85%11/12/2025 (Estimated)PBYIPuma Biotechnology$30.28M$0.984.6311.95N/A20.38%53.15%23.51%11/6/2025 (Estimated)VORVor BiopharmaN/A-$13.66N/AN/AN/AN/AN/AN/AN/ALatest MNOV, PBYI, ALLO, and VOR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025MNOVMediciNova-$0.07-$0.07N/A-$0.07N/A$0.14 million8/13/2025Q2 2025ALLOAllogene Therapeutics-$0.28-$0.23+$0.05-$0.23N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALLOAllogene TherapeuticsN/AN/AN/AN/AN/AMNOVMediciNovaN/AN/AN/AN/AN/APBYIPuma BiotechnologyN/AN/AN/AN/AN/AVORVor BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLOAllogene TherapeuticsN/A8.928.92MNOVMediciNovaN/A13.2613.26PBYIPuma Biotechnology0.101.731.62VORVor BiopharmaN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLOAllogene Therapeutics83.63%MNOVMediciNova9.90%PBYIPuma Biotechnology61.29%VORVor Biopharma97.29%Insider OwnershipCompanyInsider OwnershipALLOAllogene Therapeutics13.20%MNOVMediciNova13.60%PBYIPuma Biotechnology23.30%VORVor Biopharma0.45%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALLOAllogene Therapeutics310221.88 million192.59 millionOptionableMNOVMediciNova10N/AN/AOptionablePBYIPuma Biotechnology20050.37 million38.64 millionOptionableVORVor Biopharma140126.68 million65.45 millionNot OptionableMNOV, PBYI, ALLO, and VOR HeadlinesRecent News About These CompaniesWe Think Vor Biopharma (NASDAQ:VOR) Needs To Drive Business Growth CarefullySeptember 7 at 6:44 PM | finance.yahoo.comOMERS ADMINISTRATION Corp Takes Position in Vor Biopharma Inc. $VORSeptember 7 at 4:12 AM | marketbeat.comVor Biopharma (NYSE:VOR) Major Shareholder Reprogrammed Interchange Llc Sells 400,000 SharesSeptember 6, 2025 | insidertrades.comVor Bio Appoints Adi Osovsky, S.J.D. as General CounselSeptember 2, 2025 | globenewswire.comVor Biopharma (NYSE:VOR) Major Shareholder Reprogrammed Interchange Llc Sells 806,351 SharesSeptember 1, 2025 | americanbankingnews.comInsider Selling: Vor Biopharma (NYSE:VOR) Major Shareholder Sells 611,647 Shares of StockAugust 30, 2025 | insidertrades.comVor Biopharma (NYSE:VOR) Major Shareholder Reprogrammed Interchange Llc Sells 284,190 SharesAugust 28, 2025 | insidertrades.comVor Biopharma shares rise after collaborator’s IgAN therapy meets Phase 3 endpointAugust 28, 2025 | msn.comTelitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for IgA NephropathyAugust 27, 2025 | globenewswire.comVor Bio to Participate in Upcoming Investor ConferencesAugust 26, 2025 | globenewswire.comVor Biopharma Inc. (NYSE:VOR) Receives Consensus Recommendation of "Moderate Buy" from AnalystsAugust 26, 2025 | marketbeat.comVor Biopharma: Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 19, 2025 | finanznachrichten.deQ3 EPS Estimates for Vor Biopharma Reduced by HC WainwrightAugust 19, 2025 | marketbeat.comVor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 18, 2025 | globenewswire.comAnalysts Set Expectations for Vor Biopharma FY2028 EarningsAugust 17, 2025 | marketbeat.comWedbush Brokers Boost Earnings Estimates for Vor BiopharmaAugust 17, 2025 | marketbeat.comVor Biopharma (NYSE:VOR) Receives "Buy" Rating from HC WainwrightAugust 16, 2025 | marketbeat.comVor Biopharma Shares Soar on Positive Results for Autoimmune-Disorder TreatmentAugust 13, 2025 | marketwatch.comVor says drug licensed from RemeGen succeeded in Sjögren’s studyAugust 13, 2025 | finance.yahoo.comVor Bio Rallies On Strong Data For Autoimmune Drug CandidateAugust 13, 2025 | benzinga.comTelitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL InhibitorAugust 13, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025Kratos Keeps Climbing After Q2, But Valuation Risk LoomsBy Leo Miller | August 18, 2025Oracle Has Spoken: AI Changes EverythingBy Thomas Hughes | September 10, 2025MNOV, PBYI, ALLO, and VOR Company DescriptionsAllogene Therapeutics NASDAQ:ALLO$1.11 -0.03 (-2.63%) Closing price 04:00 PM EasternExtended Trading$1.12 +0.01 (+1.35%) As of 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.MediciNova NASDAQ:MNOV$1.27 -0.01 (-0.78%) Closing price 04:00 PM EasternExtended Trading$1.28 +0.01 (+0.79%) As of 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.Puma Biotechnology NASDAQ:PBYI$4.54 -0.17 (-3.61%) Closing price 04:00 PM EasternExtended Trading$4.54 0.00 (-0.11%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.Vor Biopharma NYSE:VOR$1.80 -0.21 (-10.45%) Closing price 04:00 PM EasternExtended Trading$1.82 +0.02 (+1.06%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Despite Pullback, Rocket Lab Still Looks Primed for a Breakout Part of the Club: Robinhood & AppLovin Soar on S&P 500 Inclusion Analyst Upgrades Strengthen Microsoft’s Long-Term Outlook Celsius Stock Surges After Blowout Earnings and Pepsi Deal Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
